assessing high-risk aml
Published 4 years ago • 144 plays • Length 3:51Download video MP4
Download video MP3
Similar videos
-
1:49
bringing precision medicine and mrd into clinical strategies
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
7:28
mbg453 with hypomethylating agents in aml and high-risk mds
-
3:52
venetoclax & aml
-
1:47
shared treatment decision-making
-
2:29
cpx-351 vs 7 3 in older high-risk aml patients
-
3:10
novel aml treament approaches
-
4:48
ruxolitinib and decitabine in patients with post-mpn aml
-
1:33
tourmaline-mm3: undetectable mrd as an endpoint for maintenance therapy
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:21
intensive therapy of older aml
-
3:11
assessment of mrd in aml
-
1:37
mrd in myeloma
-
2:14
update on the aml treatment landscape
-
3:08
hypomethylating agents in aml
-
2:16
cpx-351 in poor risk aml patients
-
1:09
taking mrd from trials to the clinic
-
4:40
management of r/r myeloma and mrd assessment
-
4:37
updates from uk ncri aml18